Gene Panel Tumor Testing in Ovarian Cancer Patients Significantly Increases the Yield of Clinically Actionable Germline Variants beyond BRCA1/BRCA2

SIMPLE SUMMARY: Germline and somatic variant testing of the BRCA1 and BRCA2 genes are important to predict treatment response to PARP inhibitors in ovarian cancer patients. However, germline variants in other genes besides BRCA1 and BRCA2 are associated with ovarian cancer predisposition, which woul...

Descripción completa

Detalles Bibliográficos
Autores principales: Barbosa, Ana, Pinto, Pedro, Peixoto, Ana, Guerra, Joana, Pinto, Carla, Santos, Catarina, Pinheiro, Manuela, Escudeiro, Carla, Bartosch, Carla, Silva, João, Teixeira, Manuel R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650720/
https://www.ncbi.nlm.nih.gov/pubmed/33008098
http://dx.doi.org/10.3390/cancers12102834

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650720/
https://www.ncbi.nlm.nih.gov/pubmed/33008098
http://dx.doi.org/10.3390/cancers12102834

Ejemplares similares